

Table S1: The plasmids used in this study and their relevant characteristics

Plasmid	Main Characteristics	Reference
pMD™-18-T	E. coli vector, AmpR, ColE1, Lac promoter, LacZ alpha terminator	Commercial stock
pGL1	Glyceraldehyde 3 phosphate dehydrogenase (gpd) promoter expressed in pMDTM-18-T vector	This study
pGL3	Hygromycin resistant gene expressed by promoter gpd in pGL1	This study
pGL3-LUP2	Amyrin synthase LUP2(Q8RWT0) from Arabidopsis thaliana expressed by gpd promoter in pGL3	This study
pGL3-bAS	Beta amylin synthase bAS(O82140) from Panax ginseng expressed by gpd promoter in pGL3	This study
pGL3-CYP716A12	Beta amylin monooxygenase CYP716A15(F6H9N6) from Vitis vinifera expressed by gpd promoter in pGL3	This study
pGL3-LUP2-CYP716A15	Amyrin synthase-Beta amylin monooxygenase expressed by gpd promoter in pGL3	This study
pGL3- bAS-CYP716A15	Beta amylin synthase-Beta amylin monooxygenase expressed by gpd promoter in pGL3	This study
pGL3- LUP2-bAS-CYP716A15	Amyrin synthase-Beta amylin synthase-Beta amylin monooxygenase expressed by gpd promoter in pGL3	This study
pGL3- LaeA-LUP2-bAS-CYP716A15	Transcription factor LaeA- Amyrin synthase-Beta amylin synthase-Beta amylin monooxygenase expressed by gpd promoter in pGL3	This study
pGL3- VeA-LaeA-LUP2-bAS-CYP716A15	Velvet protein VeA-Transcription factor LaeA- Amyrin synthase-Beta amylin synthase-Beta amylin monooxygenase expressed by gpd promoter in pGL3	This study
pGL3- VeA-VelB-LaeA-LUP2-bAS-CYP716A15	Velvet protein VeA-VelB-Transcription factor LaeA- Amyrin synthase-Beta amylin synthase-Beta amylin monooxygenase expressed by gpd promoter in pGL3	This study
pGL1-AsCpf1	CRISPR-AsCpf1 sequence expressed by gpd promoter in pGL1	This study
pGL1-LS sgRNA	CRISPR-AsCpf1 sgRNA sequence expressed by gpd promoter in pGL1	This study
pGL1-LS sgRNA-AsCpf1	CRISPR-sgRNA-AsCpf1 sequence expressed by gpd promoter in pGL1	This study
pGL1-Hgr-LS sgRNA-AsCpf1	Hygromycin resistant gene and CRISPR-LS-sgRNA-AsCpf1 sequence expressed by gpd promoter in pGL1	This study

Table S2: Primers for plasmids construction used in this study

Primers	Sequence (5'-3')	For plasmid
gpd -F	gtccggcgtagccttaggatcgaCatcgatGtTGTGAGAAAGAGACGAGGTG	pGL1
gpd -R	tatagtcgactcctctttcgtagccGCGGCGTCTAAGTAGCCTCAAAC	pGL1
HgR-F	GTTTGGCCCCCTTCTCACAGGTCAAGcctgaactcaccgcgacgtctg	pGL3
HgR-R	ACAGTCCCCAAACGCACATtctcGGTACCtattcctttgccctcggacg	pGL3
LUP2-F	GTTTGGCCCCCTTCTCACAGGTCAATGGAAACTTAAAATCGGAGAAGGCA	pGL3-LUP2
LUP2-R	GTCCCCAAACGCACATtctcGGTACCCTTATTACAGGTCTGGTGGCGGCAAT	pGL3-LUP3
bAS-F	AtaaccgcagGtaaccgcagTGGAACCTTAAAATTGCCGAGGG	pGL3-bAS
bAS-R	GCACATtctcGGTACCCTTATTAATTGTTCTCAAGAGGGAGAAGGA	pGL4-bAS
CYP716A15-F	CAGGTCAAGtaaccgcagGAACCTAACTTCTACCTTTCTCTGC	pGL3-CYP716A15
CYP716A15-R	CAAACGCACATtctcGGTACCCTAAGCTTTGTGGGGGTACAG	pGL3-CYP716A15
LUP2-CYP716A15-F	GtaaccgcagGAACCTAACTTCTACCTTTCTCTGCTGCTGCTGTTTGTTA	pGL3-LUP2-CYP716A15
LUP2-CYP716A15-R	AAGACCTCCCTATTCGTCTGTACCCCCACAAAGCTTAAGGTACCgagaAT	pGL3-LUP2-CYP716A15
bAS-CYP716A15-R	AtaaccgcagGtaaccgcagTGGAACCTTAAAATTGCCGAGGGTCAAAC	pGL3- bAS-CYP716A15
bAS-CYP716A15-R	GTCCCCAAACGCACATtctcGGTACCCTTATTAATTGTTCTCAAGAGGGAG	pGL3- bAS-CYP716A15
LUP2-bAS- CYP716A15-F	CCCTTCTCACAGGTCAATGGAAACTTAAAATCGGAGAAGGCAACGGCGA	pGL3- LUP2-bAS- CYP716A15
LUP2-bAS- CYP716A15-R	CCAGGACCTGTAATAAGGTACCgagaATGTGCGTTTGGGGACTGTTCTGAG	pGL3- LUP2-bAS- CYP716A15
LaeA-LUP2-bAS- CYP716A15-F	CTTGGCCCCCTTCTCACAGGTCAAGTCTCGTGTGGATCCCGTCCAATTCA	pGL3- LaeA-LUP2-bAS- CYP716A15
LaeA-LUP2-bAS- CYP716A15-R	AGTCCCCAAACGCACATtctcGGTACCCTTATAATGCTTTTCTTCGTGCGT	pGL3- LaeA-LUP2-bAS- CYP716A15
VeA-LaeA-LUP2- bAS-CYP716A15-F	AGTCCCCAAACGCACATtctcGGTACCCTTATCCGACAACCTCATAGAGAG	pGL3- VeA-LaeA-LUP2- bAS-CYP716A15
VeA-LaeA-LUP2- bAS-CYP716A15-R	TCATCGTTTGGCCCCCTTCTCACAGGTCAAGTTTCTTATCCTCTGCTTTA	pGL3- VeA-LaeA-LUP2- bAS-CYP716A15
VeA-VelB-LaeA- LUP2-bAS- CYP716A15-F	CAAACGCACATtctcGGTACCCTAATCGTAATCATCACCGTCATCATCAT	pGL3- VeA-VelB-LaeA- LUP2-bAS-CYP716A15
VeA-VelB-LaeA- LUP2-bAS- CYP716A15-R	GTTTGGCCCCCTTCTCACAGGTCAAATGTATGCTATCGAGGAGCGAGCTC	pGL3- VeA-VelB-LaeA- LUP2-bAS-CYP716A15
AsCpf1-F	TTTGGCCCCCTTCTCACAGGTCAAGacacagttcgagggtttac	pGL1-AsCpf1
AsCpf1-R	GCACATtctcGGTACCtctcagatttactttttctttttgcct	pGL1-AsCpf1
LS sgRNA-F	CCCCCTTCTCACAGGTCAAGtaatttactctttagatAAGGCACGCGCATGCCTCCA	pGL1-LS sgRNA
LS sgRNA-R	taatttactctttagatAAGGCACGCGCATGCCTCCAatctgagagGGTACCgagaATG	pGL1-LS sgRNA
LS sgRNA-AsCpf1-F	gtatcaggtgagcaagactgcggtt	pGL1-LS sgRNA-AsCpf1
LS sgRNA-AsCpf1-R	acaaaaggccggcggccacgaaaaggccggcc	pGL1-LS sgRNA-AsCpf1
Hgr-LS sgRNA- AsCpf1-F	TTTGGCCCCCTTCTCACAGGTCAAGcctgaactcaccgcgacgtctgctg	pGL1-Hgr-LS sgRNA- AsCpf1
Hgr-LS sgRNA- AsCpf1-R	actcgtccgagggcaaaggaatagGGTACCgagaATGTGCGTTTGGGGA	pGL1-Hgr- sgRNA-AsCpf1

Table S3: RT-qPCR primers used in this study

Enzyme	Type	Sequence	Start	Length	Tm	GC Percent
HMGR	HMGR-Forward Primer	GAGGTTTCGTATCAAGAAGG	1180	22	62.103	50
	HMGR-Reverse Primer	GAGACAAGACTCCGCAATAG	1288	21	61.856	52.381
MVK	MVK-Forward Primer	CCGTCCCTATGTATGGCTATTC	527	22	60.56	50
	MVK-Reverse Primer	ATTGTCGGAGTATGGTGTGGA	863	21	61.78	50
SQS	SQS-Forward Primer	CAAGGAAGTGGAGGGTGATTTA	201	22	61.968	45.455
	SQS-Reverse Primer	TGTGGAATTGTCGGAGTATGG	331	21	61.908	47.619
SE	SE-Forward Primer	GCTATCCCGTCCCTATGTATG	1350	22	61.703	50
	SE-Reverse Primer	CAGTGAAGAAGTGTGCGAAGA	1461	21	61.665	47.619
LS	LS-Forward Primer	GCGCTCATGTACGCGAAATA	1960	20	62.866	50
	LS-Reverse Primer	CTTGTTGAACACGCCCTCTATC	2082	22	62.903	50
18S rRNARna	18S Rrna-Forward Primer	CCTCGACGAAGTGCCATTTA	426	20	62.06	50
	18S Rrna- Reverse Primer	GCCAGGGTTTCCCATAGTTTA	523	21	62.039	47.619

Table S4: Molecular characteristics and origin of major genes used in this study

Gene/Origin	Amino acids (base pairs)	Protein homologue in <i>Ganoderma</i> spp.	Similarity/Identity (%)	Proposed function in the engineered mushroom
LUP2/ <i>Arabidopsis thaliana</i>	763(2683)	<i>G. lucidum</i> LSS	46/52	Converts 2,3-oxidosqualene to lupeol, beta-amyrin and alpha-amyrin
bAS/ <i>Panax ginseng</i>	763(2298)	<i>G. lucidum</i> LSS	53/58	Converts 2,3-oxidosqualene into beta-amyrin
CYP716A15/ <i>Vitis vinifera</i>	480(1443)	<i>G. leucocontextum</i> Cytochrome P450	27/28	Catalyzes the carboxylation of beta-amyrin, alpha-amyrin and lupeol to form oleanolic acid ursolic acid and betulinic acid respectively.
VeA/ <i>Ganoderma leucocontextum</i>	196(588)	<i>G. leucocontextum</i> VeA	100/100	Forms a heterodimer with VeIB and stimulates spore development and fruiting body formation
VeIB/ <i>Ganoderma leucocontextum</i>	531 (1593)	<i>G. leucocontextum</i> VeIB	85.38/85	Forms a heterodimer with VeA and stimulate the formation of fruiting bodies
LaeA/ <i>Ganoderma lucidum</i>	378(1137)	<i>G. lucidum</i> LaeA	96.83/97	Regulator secondary metabolism and the development of the mushroom

Table S5: Ganoderic acid profile produced by the GLE029 strain

Name	mz	HPLC-MS/MS fragments	Actual mass	Retention time (RT)	Formular	Quantification (g/L)	
						pGL3	GLE029
Ganoderic acid B*	516.691	501.11025, 483.1627	516.7	2.1002	C30H44O7	0.001	0.1212
Ganoderenic acid D	535.2648691	511.26307, 494.8652	512.6	2.2355	C30H40O7	0.004	0.1032
Ganoderic acid alpha	595.2994325	497.95117, 480.67152	574.7	2.5987	C32H46O9	0	0.07211
Ganoderenic acid B	497.2915517	513.08641, 495.18923	514.6	2.8195	C30H42O7	0	0.03
Ganoderic acid F*	612.3203967	511.0825, 495.16723	570.7	3.0615	C32H42O9	0	0.005
Ganoderic acid I*	553.2723296	515.6728, 495.16723	532.7	3.5889	C30H44O8	0.07	0.208
Lucidenic acid E2	499.2700904	480.7825	516.6	3.8167	C29H40O8	0.008	0.1036
Lucidenic acid K	493.2140903	475.2711	472.6	3.8738	C27H36O7	0	0.06
Lucidenic acid L	509.223562	501.83623	474.6	3.9595	C27H38O7	0	0.01
Lucidenic acid J*	1025.513618	513.17298, 452.8923	490.6	4.0023	C27H38O8	0.04	0.05
Lucidenic acid E*	1031.517413	516.17263, 485.16728	515.6	4.3444	C29H40O8	0.01	0.04
Ganoderic acid G*	1082.594045	531.02671, 513.02671	532.7	4.9426	C30H44O8	0	0.06
Ganoderic acid theta	553.276101	551.26712, 497.51728	530.6	5.3417	C30H42O8	0	0.007
Ganoderiol D	453.3361445	411.36728, 267.81627	488.7	5.89725	C30H48O5	0.006	0.005
Ganoderic acid A*	516.309	515.36722, 497.10836	516.7	7.25	C30H44O7	0.008	0.06
Lanosterin*	427.3890524	427.67318	426.7	8.6332	C30H50O	0.03	0.06

*Means compound verified with the authentic standard

Table S6: Quantification of the meroterpenoids produced by the GLE029 strain

Name	mz	HPLC-MS/MS mz fragments	Actual mass	Retention time (RT)	Formular	Quantification (g/L)	
						pGL3	GLE029
10'-Hydroxy-GHQ	261.1496	290.11136, 291.12360	262.34	12.093	C16H22O3	0	1.57
(+)-chizhine A	289.10809	265.14789	290.31	7.785	C16O18O5	0	2.36
(+)-chizhine C	305.10275	306.10617, 307.10818	306.31	6.486	C16H18O6	0.38	6.79




Fig. S1: (a) The illustrative metabolic map of the co-expressed -LUP2- bAS -CYP716A15 pathway. (b) The biosynthetic gene clusters in the mushroom mycelium. The clusters in green colour are the 11 nonribosomal peptide synthases (NRPS); the clusters in brown colour are the 4 polyketide synthases (PKS), and the purple cluster is the terpene gene clusters. (c) The reconstructed terpene gene cluster in the mushroom.





Fig. S2: The biosynthetic gene clusters from the sequenced genome of the fruitlet of the mushroom. The clusters in green colour are the six (6) nonribosomal peptide synthetases (NRPS); the clusters in brown colour are the five (5) polyketide synthetases (PKS), and the purple cluster is the fifteen (15) terpene gene clusters; the blue colours are the four (4) RiPP, and the light blue are the two (2) hybrid gene clusters. (b) The UGENE-based structural analysis of the VeA – VeB- LaeA proteins and their proposed reaction mechanism. (c-d) The HPLC and LC-MS/MS of the meroterpenoids.



pGL3 strain (control)




SSG medium




After 15 days fermentation at 30 degree and 200 rpm



GLE029 strain



SSG medium



After 15 days fermentation at 30 degree and 200 rpm

Fig. S3: The morphological appearance of the GLE029 and pGL3 strain (control) and its fermentation products




Fig. S4: The ^1H NMR Spectrum of (1) (^1H NMR (400 MHz, CDCl_3))




Fig.S5: The ^{13}C NMR spectrum of (1). (^{13}C NMR (101 MHz, CDCl_3))




Fig. S6: The DEPT spectrum of **(1)**

Supplementary Methodology

LC-MS/MS CONDITIONS

The LC-MS/MS was run in both ESI positive and ESI negative ion modes. An Accucore™ C18 HPLC column (2.6µm, 2.1x150mm) was used for both positive and negative ESI modes. The mobile phase consisted of 0.1% formic acid in water (phase A) and methanol (phase B), and separation was achieved using the following gradient: 0min 5% B; 0.5 min, 5%B; 13min, 95%B; 16.9min 95%B; 17min, 5%B; 20min, 5%B. The flow rate was 0.3mL/min, and the column temperature was 45 °C. The injection volume was 1 µL. The mass range was from m/z 100 to 1,000. The resolution was 70,000 for the full MS scans and 17,500 for HCD MS/MS scans. The Collision energy was set at 20, 50, 80eV. The mass spectrometer operated as follows: spray voltage, 3,800 V (+) and 3,200 V (-); sheath gas flow rate, 40 arbitrary units; auxiliary gas flow rate, 8 arbitrary units; capillary temperature, 320°C; Probe Heater Temperature, 350°C; S-lens RF level, 50.